ArticleThe Lancet. Oncology2016
Diminished but not dead: chemotherapy for the treatment of NSCLC.
Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy.MedComm · 2025Review
- AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma.British journal of cancer · 2025Article
- TLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma.Biomedicines · 2025Article
- Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.Frontiers in immunology · 2025Review
- Role of STING in the treatment of non-small cell lung cancer.Cell communication and signaling : CCS · 2024Review
- Photonanozyme-Kras-ribosome combination treatment of non-small cell lung cancer after COVID-19.Frontiers in immunology · 2024Review
- Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Frontiers in immunology · 2024Review
- The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer.Cancers · 2023Review
- Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.Current oncology (Toronto, Ont.) · 2023Review
- cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer.Current cancer drug targets · 2023Review
- Expert consensus on perioperative treatment for non-small cell lung cancer.Translational lung cancer research · 2022Review
- Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.Nature reviews. Clinical oncology · 2021Review
- Article
- Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.Cancer science · 2020Article
- In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer.Translational cancer research · 2020Article
- Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.Targeted oncology · 2019Review
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.Journal for immunotherapy of cancer · 2018Article
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27819227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.